Region MidtJylland Denmark

• Berit Andersen

  Lead investigator

• Sisse Njor

  Lead investigator

• Esben Søndergaard

  Lead investigator

• Henrik Saabye Wiggers

  Lead investigator

Sources: openalex.org

• NCT07659184

  Collaborator, Phase 4, Not yet recruiting, 528 people, 22 Jun 2026

• NCT07577596

  Collaborator, Phase 4, Recruiting, 436 people, 11 May 2026

• NCT05422001

  Collaborator, Phase 4, Terminated, 116 people, 16 Jun 2022

• NCT04376216

  Phase 4, Recruiting, 110 people, 6 May 2020

• NCT01414569

  Collaborator, Phase 4, Completed, 97 people, 11 Aug 2011

• Novo Nordisk Foundation

  Conferences, Symposia and Workshops, FUTURE OF CANCER SCREENING – 2026 PERSPECTIVE, nnf-grant-30ae7a84e54df11b, DKK 161.8k, 2026, 1 Jan 2026

• Danmarks Frie Forskningsfond

  DFF-Forskningsprojekt1, PREVENTION, OVERDETECTION AND OVERDIAGNOSIS IN COLORECTAL CANCER SCREENING (INCIDENCE), 3101-00377A, DKK 2.1m, 2023–2026, 1 Nov 2023

• Danmarks Frie Forskningsfond

  Delestillinger | Sundhed og Sygdom, The metabolic effects of SGLT2 inhibitors – Does the increase in ketone bodies protect the heart and the kidney?, 7016-00173A, DKK 383.7k, 2017–2019, 1 Sept 2017

• Danmarks Frie Forskningsfond

  DFF-Forskningsprojekt2, DanHeart: Hydralazine-ISDN and Metformin in Patients With Chronic Heart Failure. A Randomized, Double-blind, Placebo Controlled Multicenter Study., 6110-00263A, DKK 2.6m, 2016–2021, 1 Jul 2016

Sources: openalex.org